2025-12-07 - Analysis Report
Here's a breakdown of the Albemarle Corp (ALB) stock analysis based on the provided data:

**0) Report Structure:**

*   **Company Overview & Relative Performance:** High-level comparison against the S&P 500 (VOO).
*   **Historical Analysis:** Examines CAGR, MDD, Alpha, and Beta over different periods.
*   **Recent Price Action:** Looks at moving averages.
*   **Technical Indicators & Outlook:** Analyzes RSI, PPO, and the Hybrid Signal.
*   **News & Analyst Sentiment:** Summarizes recent news headlines, analyst ratings, and target prices.
*   **Financial Performance:** Reviews recent earnings and profitability.
*   **Summary:** A conclusion summarizing key findings.

**1) Company Overview & Relative Performance**

*   **ALB Company Overview:** Albemarle Corp is a global specialty chemicals company and is one of the world's largest lithium producers.
*   **Cumulative Return (ALB):** 21.91%
*   **Cumulative Return (VOO):** 100.58%
*   **Divergence:** -76.5 (ALB significantly underperforming VOO)
*   **Relative Divergence:** 14.2 (Indicates ALB is near the lower end of its historical divergence range compared to VOO)

**Analysis:** Albemarle has significantly underperformed the S&P 500 (VOO) based on cumulative returns. The negative divergence shows a substantial performance gap. The relative divergence suggests that ALB's underperformance is toward the more extreme end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 85.0%   | 68.0%   | 56.0%   | 0.1    | 14.9   |
| 2016-2018  | 9.0%    | 68.0%   | -6.0%   | 0.0    | 9.0    |
| 2017-2019  | -44.0%  | 73.9%   | -66.0%  | 0.1    | 8.5    |
| 2018-2020  | 44.0%   | 79.4%   | 20.0%   | 0.2    | 17.2   |
| 2019-2021  | 149.0%  | 79.4%   | 103.0%  | -0.1   | 27.2   |
| 2020-2022  | 148.0%  | 79.9%   | 149.0%  | 0.5    | 25.3   |
| 2021-2023  | -26.0%  | 81.9%   | -27.0%  | 0.5    | 16.8   |
| 2022-2024  | -152.0% | 81.9%   | -172.0% | 0.3    | 10.0   |
| 2023-2025  | -199.0% | 81.9%   | -265.0% | -0.9   | 14.7   |

**Analysis:**

*   **CAGR:** Fluctuates significantly, with strong growth periods followed by substantial declines, especially in recent years.
*   **MDD:** High Maximum Drawdown figures indicate considerable volatility and risk.
*   **Alpha:** Recent negative alpha values suggest underperformance relative to its risk-adjusted expected return (based on Beta and the market return).
*   **Beta:** Beta values have been generally low, suggesting low volatility of the stock, but some periods show negative values, perhaps due to external factors affecting performance (macroeconomic trends, supply chain issues, etc.).
*   **Cap(B):** Market capitalization has varied, reflecting investor sentiment and company performance.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 126.49
*   **Last Market Data:** Price: 125.19, Previous Close: 119.14, Change: 5.08
*   **5-day SMA:** 127.50
*   **20-day SMA:** 115.23
*   **60-day SMA:** 97.73

**Analysis:** The stock price is above its 20-day and 60-day moving averages, indicating a recent upward trend. However, the price is slightly below its 5-day SMA, which suggest a potential for a minor correction. The significant change from the previous close (5.08) suggests a recent volatile move, likely related to the recent news headlines.

**3) Technical Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 67.16 (Approaching overbought territory)
*   **PPO:** 0.1358 (Positive, suggesting upward momentum)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90)" - Suggests a strong buy signal based on the algorithm.
*   **Recent (20 days) relative divergence change:** 1.3 (+), indicates a short-term increase.
*   **Expected Return (%):** 118.1% (Significant potential long-term return compared to the S&P 500).

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI approaching 70 suggests the stock may be overbought and due for a pullback.
*   The PPO confirms the recent upward momentum.
*   The Hybrid Signal gives a strong buy signal, with high investment recommendation due to high returns and Very Safe - MRI:0.90.
*   The high expected return is a positive signal for long-term investors.

**4) Recent News & Significant Events**

*   **Key Themes:** The news headlines indicate a recent rally in Albemarle's stock price and focus on whether the gains are sustainable. Analysts are assessing the company's valuation and revenue streams. UBS upgraded Albemarle's price target to $185.

**Analysis:** The news is generally positive in the short term, supporting the recent price increase. However, the emphasis on sustainability suggests caution about the long-term outlook. The analyst upgrade from UBS is a significant bullish signal.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (Mean = 2.50)
*   **Target Price:** Average: $111.53, High: $200.00, Low: $58.00

**Analysis:**

*   The analyst consensus is currently a "Hold," indicating a neutral sentiment overall.
*   The wide range in target prices ($58 to $200) suggests significant disagreement among analysts regarding the stock's future value. The current price ($126.49) is above the average target price, suggesting it may be overvalued according to the average analyst expectation.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-11-05 | -1.72  | 1.31 B$   |
| 2025-08-04 | -0.16  | 1.33 B$   |
| 2025-04-30 | 0      | 1.08 B$   |
| 2024-11-06 | -9.45  | 1.35 B$   |
| 2025-11-05 | -9.45  | 1.35 B$   |

**Analysis:**

*   The recent EPS figures are mostly negative, indicating profitability challenges. It should be only 2024-11-06 in the table.
*   Revenues have been relatively stable in the $1.08B - $1.35B range.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $1.31B    | 8.99%         |
| 2025-06-30   | $1.33B    | 14.80%        |
| 2025-03-31   | $1.08B    | 14.51%        |
| 2024-12-31   | $1.23B    | 11.22%        |
| 2024-09-30   | $1.35B    | -7.68%        |

Capital and Profitability:

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $10.00B   | -1.61%  |
| 2025-06-30   | $10.24B   | 0.22%   |
| 2025-03-31   | $10.03B   | 0.41%   |
| 2024-12-31   | $9.96B    | 0.76%   |
| 2024-09-30   | $10.24B   | -10.44% |

**Analysis:**

*   **Revenue:** Shows a moderate level of consistency.
*   **Profit Margin:** Has fluctuated, with a negative value in 2024-09-30 and a generally positive trend.
*   **Equity:** Stable around $10 billion.
*   **ROE:** Has fluctuated significantly, showing net losses for the most recent quarter (2025-09-30).

**7) Comprehensive Analysis (Summary)**

*   **Underperformance:** Albemarle has significantly underperformed the S&P 500, with the relative divergence suggesting this is near the lower end of its historical range.
*   **Volatility:** High MDD values in the historical analysis highlight the stock's volatility.
*   **Recent Momentum:** Recent price action is positive, with the stock price above its 20-day and 60-day moving averages.
*   **Mixed Signals:** Technical indicators give mixed signals. RSI is approaching overbought levels, while the PPO confirms upward momentum. The Hybrid Signal gives a strong buy recommendation.
*   **Analyst Sentiment:** Analyst sentiment is neutral (Hold), with a wide range in target prices.
*   **Financial Challenges:** Recent earnings show negative EPS, and ROE fluctuates.
*   **News Catalyst:** Recent positive news, particularly the UBS upgrade, seems to have triggered a price rally.

**Conclusion:**

Albemarle is showing signs of a potential rebound based on recent price action and positive news. However, underlying financial performance (negative earnings, ROE) and neutral analyst sentiment suggest caution. The high expected return should also be taken with caution because there are financial challenges. Before making any investment decisions, one should carefully consider their own risk tolerance and consult with a financial professional.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.